

Hepatitis C in Primary Care & Drug and Alcohol Settings

Treating hepatitis C in people who inject drugs

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infections. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.

With the advent of new, well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is an opportunity to vastly improve the health outcomes of people living with HCV.

This program is designed for addiction medicine specialists, OST prescribers, family physicians and other medical staff working with people who inject drugs. Through online learning and a face-to-face workshop, delivered by local experts, participants will gain the skills to confidently manage hepatitis C in their setting.

Upon completion of this program, participants will be able to:

- Describe the risk factors for HCV infection, enabling effective practice screening processes and prevention education
- Demonstrate competence interpreting clinical information to effectively diagnose HCV
- Demonstrate competence in liver disease assessment
- Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy
- Monitor patients on treatment and post-treatment appropriately

This workshop will be held adjacent to the Canadian Society of Addiction Medicine Annual Meeting and Scientific Conference.

Date:

Sunday, 28 October 2018

Time:

8:30am - 4:00pm

Venue:

Fairmont Hotel Vancouver
900 West Georgia Street
Vancouver, BC, V6C 2W6

Cost:

The course is free of charge and fully catered. Places are limited - registration is essential.

Registration link:

www.inhsueducation.org/canada/workshops

Register before:

Thursday, 18 October 2018

More information:

For further details or for information about travel scholarships contact: info@inhsu.org.au

Certification

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and accredited by the Canadian Association for the Study of the Liver. Participants can claim up to a maximum of 6.0 study credits. This Group Learning program has also been reviewed by the College of Family Physicians of Canada and is awaiting provincial certification by the College's BC Chapter.

About INHSU

This Symposium is convened by the International Network on Hepatitis in Substance Users (INHSU), an international organisation dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs.

This workshop has been funded through an unrestricted grant from Gilead Sciences Canada Inc. Gilead have had no input into the tone, content or emphasis of the material used at this course.

